Contract drug manufacturing (CDMO) stocks
CDMO
What are Contract drug manufacturing (CDMO) stocks in Korea?
The Contract drug manufacturing (CDMO) theme on jonbur groups 22 Korean stocks listed on KOSPI and KOSDAQ, worth ₩125T in total. On Oct 29, 2026 the group moved down 0.15% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Hanmi Pharm.
Key facts
- Stocks
- 22
- Total market value
- ₩125T
- Day's move
- −0.15%
- As of
- Oct 29, 2026
- Largest members
- Samsung Biologics, Celltrion, Hanmi Pharm
Earnings tracker · 3Q 2026
Reporting season · reports due by Nov 14
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Celltrion | Oct 12Preliminary | ₩1.5T | +45.8% | ₩510B | +69.2% | +12.9% | 34.0%29.3% |
| Hanmi Pharm | Oct 27Preliminary | ₩377B | +4.2% | ₩38B | −31.3% | −71.2% | 10.0%15.2% |
| ST Pharm | Oct 27Preliminary | ₩98B | +19.1% | ₩16B | +6.6% | −14.3% | 16.1%18.0% |
| Dong-A ST | Oct 27Preliminary | ₩207B | −4.4% | ₩21B | +52.9% | +239.9% | 10.4%6.5% |
| Samsung Biologics | Expected around Oct 28 | ||||||
| GC Biopharma | Expected around Nov 3 | ||||||
| Chong Kun Dang Pharmaceutical | Expected around Nov 3 | ||||||
| IL Dong Pharmaceutical | Expected around Nov 6 | ||||||
| Daewoong Pharma | Expected around Nov 7 | ||||||
| Huons | Expected around Nov 10 | ||||||
| GL Pharm Tech | Expected around Nov 10 | ||||||
| SAM Chun Dang Pharm | Expected around Nov 14 | ||||||
| Proteina | Expected around Nov 14 | ||||||
| Samyang Holdings | Expected around Nov 14 | ||||||
| Binex | Expected around Nov 14 | ||||||
| Kolon Life Science | Expected around Nov 14 | ||||||
| BNC Korea | Expected around Nov 14 | ||||||
| Prestige Biologics | Expected around Nov 14 | ||||||
| RPbio | Expected around Nov 14 | ||||||
| SeouLin Bioscience | Expected around Nov 14 | ||||||
| Dt&Cro | Expected around Nov 14 | ||||||
| IMBiologics | Not yet | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 29, 2026- Above 20-day average
- 18.2%
- Above 60-day average
- 22.7%
- RSI above 70
- 0%
- RSI below 30
- 13.6%
- 52-week highs
- 0
- 52-week lows
- 1
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The contract drug manufacturing (CDMO) theme covers 22 member stocks, and only 18.2% trade above their 20-day averages while 22.7% sit above their 60-day averages. Breadth is weak: no member is currently at a 52-week high, one is at a 52-week low, and the lowest member RSI is 13.6, with no member showing an RSI extreme on the high side. The equal-weighted member index is labeled bearish on both the short and medium horizons, with its RSI at 38.1 and its price below the cloud.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesOct 23, 202685GC Biopharma: ₩130bn of bonds due in the next 6 months vs ₩42bn cash₩130bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.GC Biopharma
Creators talking about this
Contract drug manufacturing (CDMO)
−8.21%CDMO
The CDMO (contract development and manufacturing organization) theme covers Korean companies that develop and manufacture pharmaceuticals, biologics, and related products on behalf of other drug companies, rather than selling their own branded medicines. Korean investors often group these firms together because they share a business model centered on large-scale bioproduction capacity, long-term client contracts, and exposure to the global biopharma outsourcing trend. The theme is also frequently linked to the broader Korean biotech sector, so its share prices tend to move alongside related names.
22 companies · 4 up · 0 flat · 18 down
- Traded value
- ₩246B
- Value vs 20-day average
- 0.75×
- Top gainer
- SAM Chun Dang Pharm +16.06%
- Largest company
- Samsung Biologics ₩63T
Companies in this theme
| Company | Price | Monthly | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,366,000 | −2.43% | ₩58B | ₩63T | 6.88% |
Celltrion068270 · KOSPI | ₩189,300 | +6.17% | ₩71B | ₩44T | 7.28% |
Hanmi Pharm128940 · KOSPI | ₩388,500 | −22.92% | ₩63B | ₩5T | 9.61% |
GC Biopharma006280 · KOSPI | ₩132,000 | +7.14% | ₩1.9B | ₩1.5T | 6.68% |
Daewoong Pharma069620 · KOSPI | ₩101,500 | −6.28% | ₩1.7B | ₩1.2T | 10.30% |
Chong Kun Dang Pharmaceutical185750 · KOSPI | ₩62,500 | −4.43% | ₩703M | ₩863B | 6.34% |
Samyang Holdings000070 · KOSPI | ₩52,500 | −9.95% | ₩323M | ₩408B | 2.68% |
IL Dong Pharmaceutical249420 · KOSPI | ₩12,570 | −10.60% | ₩7.8B | ₩398B | 2.30% |
Dong-A ST170900 · KOSPI | ₩34,000 | −2.58% | ₩399M | ₩331B | 4.78% |
Source: KRX statistical information